The Portfolio returned 7.33% gross, significantly outperforming the MSCI World Health Care Index's 3.12% return. Click here ...

REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...

We have an emerging new entrant in the increasingly crowded weight loss drug space.

Then, life science companies were scrambling for space — industrial vacancy rates dipped to as low as 2%. Deep‑pocketed developers from Silicon Valley and Boston came and spent millions speculating on ...

Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 clinical study of WVE-007, its obesity ...

Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative ...

The 2024-25 Sustainability Report reflects the company’s long-term view-one that places science, responsibility, and ...

The developer behind Philadelphia's largest life sciences building says the market needs patience after venture capital ...

Actively moving up the value chain toward drug discovery, development and digital therapeutics is key to sustaining the State ...

The Board on Life Sciences (BLS) was established in 1984 to serve as the focal point for addressing critical, emerging policy and technical issues associated with the life sciences and biotechnology ...